Table 2.
Overview of the analytical performances of the major chemosensitivity assays described in the literature against a large array of solid cancers
| Assay | Cancer | Success rate | Accuracy | PPV | NPV | Cohort size (number of patients) | Sensitivity | Specificity | Authors | References |
|---|---|---|---|---|---|---|---|---|---|---|
| ATP | Gastrointestinal | 85.0% | 84.0% | - | - | 25 | 64.0% | 100.0% | Kawamura et al., 1997 | 41 |
| ATP | Ovary | 89.0% | 71.0% | 66.0% | 89.0% | 93 | 95.0% | 44.0% | Konecny et al., 2000 | 42 |
| ATP | Ovary | 85.0% | 85.0% | 50.0% | 100.0% | 33 | 100.0% | 82.0% | Ng TY et al., 2000 | 43 |
| ATP | Ovary | - | 70.7% | 83.0% | 56.5% | 161 | 68.8% | 74.3% | O'Meara et al., 2001 | 44 |
| ATP | Lung | 90.6% | 90.0% | 100.0% | 80.0% | 31 | 83.3% | 100.0% | Kim BS et al., 2004 | 45 |
| ATP | Lung | 90.6% | - | - | - | 53 | - | - | Kang et al., 2005 | 22 |
| ATP | Lung | 43.8% | 68.8% | 61.1% | 78.6% | 34 | - | - | Moon YW et al., 2007 | 46 |
| ATP | Breast | 93.0% | 85.0% | 100.0% | 66.7% | 43 | 78.6% | 100.0% | Kim et al., 2008 | 47 |
| ATP | Ovary | 69.0% | 90.0% | 94.1% | - | 29 | 94.1% | - | Han et al., 2008 | 48 |
| ATP | Gastrointestinal | 95.8% | 77.8% | 85.7% | 75.9% | 36 | 46.2% | 95.7% | Kim JH et al., 2010 | 49 |
| ATP | Colon | 79.0% | - | 94.0% | 38.0% | 62 | - | - | Lee et al., 2011 | 50 |
| ATP | Bladder | 96.3% | 74.3% | 83.7% | 66.7% | 54 | 97.6% | 20.0% | Ge et al., 2012 | 51 |
| ATP | Ovary | - | - | 83.0% | 84.8% | 80 | 88.6% | 77.8% | Zhang et al., 2015 | 52 |
| HDRA | Head and Neck | 88.0% | 74.0% | 83.0% | 64.0% | 26 | 71.0% | 78.0% | Robbins et al., 1994 | 53 |
| HDRA | Gastric & Colon | 96.3% | - | 66.7% | 100.0% | 38 | 100.0% | 90.6% | Furukawa et al., 1995 | 54 |
| HDRA | Ovary | 97.0% | 87.0% | 88.0% | 86.0% | 15 | 88.0% | 86.0% | Ohie et al., 2000 | 55 |
| HDRA | Breast | 98.8% | 80.0% | 100.0% | 70.0% | 15 | 62.5% | 100.0% | Tanino H et al., 2001 | 56 |
| HDRA | Head and Neck | 97.6% | - | - | - | 42 | - | - | Singh et al., 2002 | 57 |
| HDRA | Head and Neck | - | 91.7% | 90.0% | 100.0% | 19 | 79.0% | 66.7% | Ariyoshi et al., 2003 | 58 |
| HDRA | Head and neck | - | 77.8% | 76.9% | 80.0% | 49 | 90.9% | 57.1% | Hasegawa et al., 2007 | 59 |
| HDRA | Head and Neck | 91.0% | 74.0% | 69.0% | 80.0% | 57 | 79.0% | 71.0% | Pathak et al., 2007 | 60 |
| HDRA | Lung | 97.4% | 83.0% | 73.2% | 100.0% | 343 | 100.0% | 68.1% | Yoshimasu et al., 2007 | 61 |
| HDRA | Ovary | - | - | 62.0% | 81.0% | 61 | 90.0% | 43.0% | Neubauer et al., 2008 | 62 |
| HDRA | Oesophagus | 89.3% | - | - | - | 53 | 66.7% | 55.6%-66.7% | Fujita et al., 2009 | 63 |
| HDRA | Glioma | 94.0% | - | - | - | 33 | 100.0% | 60.0% | Gwak H et al., 2011 | 64 |
| HDRA | Colon | - | 66.3% | - | - | 86 | 72.7% | 54.7% | Yoon et al., 2012 | 65 |
| ITRA | Colon | - | 61.9% | 57.1% | 64.3% | 42 | 44.4% | 75.0% | Yoon et al., 2017 | 24 |
| ITRA | Ovary | - | 44.4% | 40.0% | 66.7% | 18 | 85.7% | 18.2% | Kim et al., 2019 | 25 |
| CD-DST | Multiple | 80.0% | 91.0% | 80.0% | 100.0% | 11 | 100.0% | 86.0% | Kobayashi et al., 1997 | 66 |
| CD-DST | Breast | 84.3% | 87-94.4% | 83.3% | 95.5-100% | 70 | 92.9% | 62.5-95.5% | Takamura et al., 2002 | 67 |
| CD-DST | Mesothelioma | - | 50.0% | - | - | 26 | 100.0% | 36.0% | Higashiyama et al., 2008 | 68 |
| CD-DST | NSCLC | - | 70.0% | 50.0% | 92.0% | 81 | 88.0% | 63.0% | Higashiyama et al., 2010 | 69 |
| CD-DST | Gastric | 80.0% | - | - | - | 64 | - | - | Naitoh et al., 2014 | 70 |
| CD-DST | OSCC | 81.8% | 92.3% | 90.9% | 100.0% | 14 | - | - | Sakuma et al., 2017 | 71 |
| FCA | Multiple | - | - | 85.0% | 97.0% | 73 | 98.0% | 81.0% | Leone et al., 1991 | 27 |
| The Oncogramme® | Colorectal | 97.4% | 63.6% | 64.7% | 60.0% | 19 | 84.6% | 33.3% | Bounaix Morand du Puch et al., 2016 | 39 |
| CANScript™ | Multiple | - | - | 93.9% | 100.0% | 55 | - | - | Majumder et al., 2015 | 37 |
| ChemoFX® | Ovary | - | - | 63.6% | 100.0% | 18 | - | - | Ness et al., 2002 | 72 |
| ChemoFX® | Breast | 83.9% | - | - | - | 62 | - | - | Mi et al., 2008 | 73 |
| ChemoFX® | Head and Neck | 72.7% | - | 81.8% | - | 22 | - | - | Jamal et al., 2017 | 74 |
| ChemoID® | Glioblastoma | - | - | 54.6% | 100.0% | 11 | 100.0% | 50.0% | Claudio et al., 2017 | 75 |
| MICK | Endometrium | 78.9% | - | - | - | 19 | - | - | Ballard et al., 2010 | 32 |
| Mean | 86.6% | 76.1% | 76.7% | 82.0% | 51.8 | 84.2% | 68.3% | |||
| Median | 89.2% | 77.8% | 82.4% | 81.0% | 40.0 | 88.0% | 72.7% |